新阿姆斯特丹制药
NAMS
19.83
-0.79
-3.83%
新阿姆斯特丹制药
US · NAMS
#2583 按市值排名
上市于 1970
19.83
-0.79
-3.83%
实时 - 追踪5344个代码 - 心跳于165秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了6家。
- 机构持股总比例下降了1.2个百分点。
机构持股
- 机构持股比例
- 105.78% -1.22pp
- 机构数量
- 246 -6
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund44.05%
VC/PE Fund36.55%
Hedge Fund17.17%
Family Office/Trust2.58%
Public Company2.51%
Private Company2.10%
Individual/Insider0.89%
Sovereign Wealth Fund0.70%
Government Pension Fund0.12%
主要股东 截至 2026-09-18
Frazier Life Sciences Management, LP
15.84% · 18.94M 股
Capital Research
11.67% · 13.95M 股
FMR
8.65% · 10.34M 股
RA Capital Management, L.P.
7.99% · 9.55M 股
Forbion Capital Partners B.V.
7.10% · 8.49M 股
Deerfield Management Company, L.P.
3.57% · 4.26M 股
Viking Global Investors LP
3.52% · 4.20M 股
Bain Capital Life Sciences Investors, LLC
3.18% · 3.81M 股
Maverick Capital, Ltd.
2.73% · 3.27M 股
Duquesne Family Office LLC
2.57% · 3.07M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 24次买入 · 26次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Frazier Life Sciences Management, LP | -- | 15.84% |
| Michael Davidson | CEO, President, Executive Board Member & Director | 0.77% |
| Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | 0.06% |
| Hilde van der Kamp | Independent Non-Executive Director | 0.03% |
| Douglas Kling | Chief Operating Officer | 0.01% |
| Mayur Somaiya | Chief Financial Officer | 0.01% |
| Adele M. Gulfo | Independent Director | 0.00% |
| Louise Kooij | Interim Chief Financial Officer | 0.00% |
| Louis Lange | Non-Executive Director | 0.00% |
| Mark McKenna | Non-Executive Director | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Derivative Exercise and Sale | -50,246 | $25.03 |
| 2026-09-13 | Michael Davidson | CEO, President, Executive Board Member & Director | Open Market Acquisition | +10,000 | $22.65 |
| 2026-09-03 | John Smither | Independent Director | Open Market Disposition | -1,600 | $25.32 |
| 2026-08-31 | Robert Gunning | Vice President | Other Acquisition | +3,200 | -- |
| 2026-08-31 | Robert Gunning | Vice President | Other Derivative Acquisition | +14,000 | $24.92 |
| 2026-08-24 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Intent to Sell (Form 144) | -250,000 | -- |
| 2026-08-23 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Derivative Exercise and Sale | -125,000 | $26.91 |
| 2026-07-19 | Louise Kooij | Interim Chief Financial Officer | Derivative Exercise and Sale | -105,000 | $11.17–31.71 |
| 2026-06-21 | Louise Kooij | Interim Chief Financial Officer | Derivative Exercise and Sale | -40,000 | $10.90–30.73 |
| 2026-05-25 | Louise Kooij | Interim Chief Financial Officer | Derivative Exercise and Sale | -65,000 | $10.00–35.69 |
| 2026-03-10 | Louis Lange | Non-Executive Director | Open Market Disposition | -44,619 | $30.41–31.23 |
| 2026-03-08 | Louis Lange | Non-Executive Director | Derivative Exercise and Retained | +44,619 | $11.50 |
| 2026-03-08 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Derivative Exercise and Sale | -300,000 | $30.29–30.32 |
| 2026-03-05 | Louis Lange | Non-Executive Director | Open Market Disposition | -28,186 | $29.41 |
| 2026-03-01 | Michael Davidson | CEO, President, Executive Board Member & Director | Derivative Exercise and Sale | -443,707 | $33.25 |
| 2026-03-01 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Intent to Sell (Form 144) | -300,000 | $31.18 |
| 2026-02-25 | Michael Davidson | CEO, President, Executive Board Member & Director | Derivative Exercise and Sale | -306,293 | $33.63–36.68 |
| 2026-02-23 | Michael Davidson | CEO, President, Executive Board Member & Director | Intent to Sell (Form 144) | -750,000 | $36.17 |
| 2026-02-19 | Johannes Jacob Kastelein | Founder, Chief Scientific Officer, Member of Executive Board & Director | Open Market Disposition | -45,481 | $35.00–35.46 |
| 2026-01-27 | Louise Kooij | Interim Chief Financial Officer | Derivative Exercise and Sale | -72,428 | $10.90–32.62 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
新阿姆斯特丹制药 讨论区 0 条评论